MaxCyte Statistics
Total Valuation
MaxCyte has a market cap or net worth of $491.88 million. The enterprise value is $353.01 million.
| Market Cap | 491.88M |
| Enterprise Value | 353.01M |
Important Dates
The last earnings date was Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MaxCyte has 104.54 million shares outstanding. The number of shares has increased by 1.21% in one year.
| Shares Outstanding | 104.54M |
| Shares Change (YoY) | +1.21% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 1.22% |
| Owned by Institutions (%) | 75.04% |
| Float | 90.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.17 |
| Forward PS | 13.24 |
| PB Ratio | 2.17 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.26, with a Debt / Equity ratio of 0.08.
| Current Ratio | 13.26 |
| Quick Ratio | 12.13 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -15.70% and return on invested capital (ROIC) is -19.35%.
| Return on Equity (ROE) | -15.70% |
| Return on Assets (ROA) | -13.70% |
| Return on Capital (ROIC) | -19.35% |
| Revenue Per Employee | $308,068 |
| Profits Per Employee | -$255,716 |
| Employee Count | 143 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.46 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +22.57% in the last 52 weeks. The beta is 1.07, so MaxCyte's price volatility has been similar to the market average.
| Beta (1Y) | 1.07 |
| 52-Week Price Change | +22.57% |
| 50-Day Moving Average | 4.16 |
| 200-Day Moving Average | 4.12 |
| Relative Strength Index (RSI) | 63.47 |
| Average Volume (30 Days) | 565,361 |
Short Selling Information
The latest short interest is 3.58 million, so 3.42% of the outstanding shares have been sold short.
| Short Interest | 3.58M |
| Short Previous Month | 3.29M |
| Short % of Shares Out | 3.42% |
| Short % of Float | 3.95% |
| Short Ratio (days to cover) | 7.67 |
Income Statement
In the last 12 months, MaxCyte had revenue of $44.05 million and -$36.57 million in losses. Loss per share was -$0.35.
| Revenue | 44.05M |
| Gross Profit | 38.91M |
| Operating Income | -47.40M |
| Pretax Income | -36.57M |
| Net Income | -36.57M |
| EBITDA | -31.74M |
| EBIT | -36.57M |
| Loss Per Share | -$0.35 |
Balance Sheet
The company has $157.51 million in cash and $18.64 million in debt, giving a net cash position of $138.87 million or $1.33 per share.
| Cash & Cash Equivalents | 157.51M |
| Total Debt | 18.64M |
| Net Cash | 138.87M |
| Net Cash Per Share | $1.33 |
| Equity / Book Value | 226.36M |
| Book Value Per Share | 2.17 |
| Working Capital | 165.20M |
Cash Flow
In the last 12 months, operating cash flow was -$27.93 million and capital expenditures -$2.95 million, giving a free cash flow of -$30.87 million.
| Operating Cash Flow | -27.93M |
| Capital Expenditures | -2.95M |
| Free Cash Flow | -30.87M |
| FCF Per Share | -$0.30 |
Margins
Gross margin is 88.32%, with operating and profit margins of -107.59% and -83.01%.
| Gross Margin | 88.32% |
| Operating Margin | -107.59% |
| Pretax Margin | -83.01% |
| Profit Margin | -83.01% |
| EBITDA Margin | -72.04% |
| EBIT Margin | -83.01% |
| FCF Margin | -70.08% |
Dividends & Yields
MaxCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.21% |
| Shareholder Yield | -1.21% |
| Earnings Yield | -7.43% |
| FCF Yield | -6.28% |
Analyst Forecast
The average price target for MaxCyte is $8.67, which is 85.65% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.67 |
| Price Target Difference | 85.65% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 28.39% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MaxCyte has an Altman Z-Score of 8.81 and a Piotroski F-Score of 3.
| Altman Z-Score | 8.81 |
| Piotroski F-Score | 3 |